Front Row Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Front Row Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-280	Closed	–	–	580
2025 Q4	$0	Buy	+280	New	–	﹤0.01%	566

Front Row Advisors's NAVB Position: Q1 2026 in Review

Front Row Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q1 2026, closing a stake of 280 shares.

Front Row Advisors first reported a position in NAVB in Q4 2025 and held it in 1 quarter. The position peaked at $0 in Q4 2025. 0 funds tracked by Wall St. Rank hold NAVB as of Q1 2026.

Front Row Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q1 2026 after selling out during the quarter.
Front Row Advisors sold 280 Navidea Biopharmaceuticals Inc. shares in Q1 2026.
Front Row Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2025 and held it in 1 quarter.
Front Row Advisors's Navidea Biopharmaceuticals Inc. position peaked at $0 in Q4 2025.
0 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.